Oral mucosal diseases: Mucous membrane pemphigoid

被引:50
作者
Scully, Crispian [1 ]
Lo Muzio, Lorenzo [2 ]
机构
[1] UCL, Eastman Dent Inst, London WC1X 8LD, England
[2] Univ Foggia, Dept Surg Sci, Foggia, Italy
关键词
pemphigoid; skin autoimmune; corticosteroids; immunosuppressants; oral;
D O I
10.1016/j.bjoms.2007.07.200
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Subepithelial vesiculobullous conditions are chronic autoimmune disorders that arise from reactions directed against components of the hemidesmosomes or basement membrane zones (BMZ) of stratified squamous epithelium to which the term immune-mediated subepithelial blistering diseases (IMSEBD) has been given. Mucous membrane pemphigoid (MMP) is the most common, but variants do exist. Non-immune disorders that involve these epithelial components typically have a genetic basis-the main example being epidermolysis bullosa. All subepithelial vesiculobullous disorders present as blisters and erosions, and diagnosis must be confirmed by biopsy examination with immunostaining, sometimes supplemented by other investigations. No single treatment reliably controls all subepithelial vesiculobullous disorders; the immunological differences within IMSEBD may account for differences in responses to treatment. Currently, as well as improving oral hygiene, immunomodulatory treatment is used to control the oral lesions of MMP, but it is not known if its specific subsets reliably respond to different agents. (C) 2007 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:358 / 366
页数:9
相关论文
共 162 条
[71]   Pure ocular cicatricial pemphigoid - A distinct immunopathologic subset of cicatricial pemphigoid [J].
Hoang-Xuan, T ;
Robin, H ;
Demers, PE ;
Heller, M ;
Toutblanc, M ;
Dubertret, L ;
Prost, C .
OPHTHALMOLOGY, 1999, 106 (02) :355-361
[72]   MANAGEMENT OF THE IMMUNOBULLOUS DISORDERS .1. PEMPHIGOID [J].
HUILGOL, SC ;
BLACK, MM .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1995, 20 (03) :189-201
[73]  
Ikegaya H, 1999, BJU INT, V83, P735
[74]   A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders [J].
Jolles, S .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2001, 26 (02) :127-131
[75]   Subepidermal blistering disease with autoantibodies against a novel dermal 200-kDa antigen [J].
Kawahara, Y ;
Zillikens, D ;
Yancey, KB ;
Marinkovich, MP ;
Nie, Z ;
Hashimoto, T ;
Nishikawa, T .
JOURNAL OF DERMATOLOGICAL SCIENCE, 2000, 23 (02) :93-102
[76]   THE USE OF CHEMICALLY SPLIT TISSUE IN THE DETECTION OF CIRCULATING ANTI-BASEMENT MEMBRANE ZONE ANTIBODIES IN BULLOUS PEMPHIGOID AND CICATRICIAL PEMPHIGOID [J].
KELLY, SE ;
WOJNAROWSKA, F .
BRITISH JOURNAL OF DERMATOLOGY, 1988, 118 (01) :31-40
[77]  
Kreyden OP, 2001, HAUTARZT, V52, P247, DOI 10.1007/s001050051299
[78]  
KUFFER R, 1996, SCI REV, P109
[79]  
Kumari S, 2001, INVEST OPHTH VIS SCI, V42, P379
[80]   Interleukin 1 components in cicatricial pemphigoid. Role in intravenous immunoglobulin therapy [J].
Kumari, S ;
Bhol, KC ;
Rehman, F ;
Foster, CS ;
Ahmed, AR .
CYTOKINE, 2001, 14 (04) :218-224